GLP-1 Drugs and Your Health Plan: What Employers Need to Decide

GLP-1 medications: drugs like Ozempic, Wegovy, Mounjaro, and Zepbound, have moved from a niche pharmaceutical category to one of the most consequential benefits decisions employers face today. If you have not yet been asked about your company's GLP-1 coverage policy by HR, employees, or a benefits consultant, you likely will be soon.

These drugs work. Clinical evidence for their effectiveness in treating type 2 diabetes and in achieving meaningful weight loss is now substantial. What makes them complicated from an employer benefits perspective is not their efficacy. It is their cost, their demand, their legal implications, and the long-term questions around who pays for what.

This article is not a recommendation to cover or not cover GLP-1s. It is a framework for making that decision deliberately.

What These Drugs Actually Cost

The list price for GLP-1 drugs ranges from approximately $900 to $1,400 per month, depending on the specific medication. Employer plans typically pay less than list price, but the net cost after rebates and negotiated rates is still commonly cited in the $600 to $750 per-member-per-month range.

To put that in context: covering a single employee on a GLP-1 medication for weight loss costs your health plan roughly as much as covering three to four average members for all of their healthcare needs combined.

The usage data is also striking. A 2025 survey from the Society for Human Resource Management found that about 23 percent of U.S. employers now cover GLP-1 drugs for weight loss in their health plans. Among large employers: those with 5,000 or more workers: that figure rises to 43 percent. For small and mid-size employers, the percentage is significantly lower.

The financial exposure is real, and it compounds. Unlike most pharmaceutical costs, GLP-1 drugs require continuous use to maintain their effects. Stopping the medication typically leads to weight regain. This is not a short-term claims event. It is a potential long-term cost commitment.

The Three Coverage Stances

Most employers today fall into one of three broad positions on GLP-1 coverage.

Cover for diabetes, not weight loss. The historical default has been to cover GLP-1 drugs when prescribed for type 2 diabetes: which is an FDA-approved indication with clinical necessity standards: while excluding coverage when prescribed specifically for weight loss or obesity. This position is administratively straightforward and still held by a majority of employers. The challenge is that the distinction is increasingly difficult to enforce cleanly, as the same drug can treat both conditions, and the prescribing diagnosis matters significantly for coverage determination.

Cover with clinical management guardrails. A growing number of employers are choosing to cover GLP-1s for weight loss but adding prior authorization requirements, BMI thresholds, mandatory lifestyle program participation, or step therapy requirements (trying lower-cost interventions first). This approach can control utilization and cost while still making coverage available to employees who meet clinical criteria. The administrative overhead is higher, and there are legal questions around which requirements can be applied without discrimination risk.

Cover without restriction. Some employers: particularly those competing for talent in high-demand industries: cover GLP-1s for both diabetes and weight loss without meaningful clinical management. This maximizes the benefit for employees and supports recruitment, but it also creates the highest cost exposure and the most difficult-to-reverse precedent. Adding coverage is typically well-received; removing it generates significant employee relations problems.

The Legal Dimension

The most consequential legal development in this space is the evolving relationship between GLP-1 coverage, obesity as a covered condition, and the Americans with Disabilities Act.

In January 2026, the EEOC issued final guidance clarifying that severe obesity qualifies as a disability under the ADA in many circumstances. This has direct implications for employer health plans. If obesity is a qualifying disability, employers may face risk if their plan covers weight loss interventions for some employees while denying coverage for others in ways that could be characterized as disability-based discrimination.

This does not mean that every employer must cover GLP-1s. But it does mean that coverage decisions should be reviewed with employment counsel or a knowledgeable benefits attorney, not made informally or by default.

The question to ask your legal advisor is not simply "are we required to cover this?" but also "could our current policy create exposure under the ADA or applicable state disability laws?"

What the Cost-Benefit Calculation Actually Looks Like

Proponents of GLP-1 coverage argue, with some data backing: that the long-term cost picture may be more favorable than the short-term premium impact suggests. Obesity is a driver of significant downstream healthcare costs: cardiovascular disease, joint deterioration, sleep apnea, type 2 diabetes itself, and other conditions that generate substantial claims over time. If GLP-1 coverage reduces these downstream costs, the net cost to the plan may be lower than it appears.

The honest answer is that the long-term data on this question is still developing. Studies are promising, but the timeframes are short, the populations studied are not always representative of employer group plan members, and the persistence of medication use in employer-covered populations is not well established.

For small and mid-size employers, the financial risk of covering GLP-1s for weight loss is more acute than for large employers, because a small number of high utilizers has a disproportionate impact on the plan and on renewal rates. A self-insured employer with 500 employees has better tools to manage this risk than a fully insured employer with 80.

Practical Steps for Employer Decision-Making

If you have not yet formally decided how your plan handles GLP-1 coverage, here is a practical sequence for making that decision thoughtfully.

First, find out what your current plan covers. Many employers are surprised to learn that their plan's existing formulary or clinical management policies already address GLP-1s: sometimes more permissively than intended, sometimes more restrictively. Before making a decision, understand what decision you have already made by default.

Second, pull your claims data. Ask your broker or PBM (pharmacy benefits manager) for utilization reports on GLP-1 drugs in your plan over the past two years. How many members are using them? For which indications? What are you currently paying? This baseline is essential for modeling the cost impact of any policy change.

Third, evaluate your risk profile. A self-insured plan has different risk characteristics than a fully insured plan. If you are fully insured, GLP-1 costs flow through your experience and affect your renewal. If you are self-insured, they affect your stop-loss and your aggregate claims. Understanding your structure determines how much cost exposure you are actually taking on.

Fourth, consult legal counsel before implementing or removing coverage. Both adding and removing GLP-1 coverage create legal considerations: ADA implications, ERISA plan amendment requirements, and state law variations that apply in some markets. This is not a decision to make without guidance.

Fifth, communicate any change clearly and with context. If you are adding coverage, explain the clinical management requirements and how employees can access the benefit. If you are restricting or removing coverage, explain the cost rationale and, where possible, acknowledge the impact on employees who may be affected. GLP-1 coverage decisions are personal for many employees. The communication matters.

What to Watch For in the Next 12 Months

Several developments are likely to materially affect this decision over the next year. FDA approvals for additional GLP-1 indications: cardiovascular outcomes, sleep apnea, and others: could change the coverage calculus by making the clinical case for these drugs broader and potentially shifting the ADA/disability analysis. Generic and biosimilar versions of GLP-1 drugs are also expected to enter the market, which could significantly reduce the cost exposure for employer plans.

Regulatory guidance is also evolving. The EEOC's obesity disability guidance is new, and its interpretation in employment litigation is still developing. Employers should monitor this space, particularly if they are in the process of designing or modifying their coverage policy.

The Bottom Line

GLP-1 coverage is not a benefits trivia question. It is a decision with real cost implications, legal dimensions, and meaningful effects on employee experience. The employers who handle it well are not necessarily the ones who decide to cover or not cover. They are the ones who make the decision deliberately, document their rationale, consult appropriate advisors, and communicate clearly with their workforce.

If your plan has not formally addressed this, now is a reasonable time to do so. The conversation is only going to become more common., -

Benefits Collective helps employers make informed decisions about health plan design, coverage policy, and renewal strategy. If you are navigating GLP-1 coverage decisions or other complex benefits questions, schedule a consultation to talk through your specific situation.